International Prospective Study on Adherence to Treatment in Patients With Active Systemic Lupus Erythematosus (Adherence-SLE)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01509989|
Recruitment Status : Completed
First Posted : January 13, 2012
Last Update Posted : July 6, 2016
The treatment of systemic lupus erythematosus (SLE) may change in the future due to the availability of new biological treatments, especially monoclonal antibodies in patients with active disease. However, one of the main causes of treatment failure in SLE is the lack of treatment adherence since "drugs don't work in patients who don't take them." Hydroxychloroquine (HCQ-Plaquenil) has a long terminal elimination half- life, and investigators have demonstrated that patients who do not take HCQ for a long time have undetectable or very-low blood HCQ concentrations (< 200 ng/ml). The rate of severe non-adherence was 7% in a cohort of 203 patients and was even higher in patients with active disease: 8 out of 35 (23%) in patients with a SLEDAI ≥6 and 6 out of 20 (30%) in patients with a SLEDAI ≥12.
Investigators will evaluate the importance of non-adherence to the treatment in a large population of SLE patients with active disease. This will be done with blood HCQ monitoring in a translational multicentric prospective study.
|Condition or disease|
|Systemic Lupus Erythematosus|
This international multicentric prospective study is an observational study that will include consecutive SLE patients treated with HCQ and with SLE flare (defined by the SELENA-SLEDAI flare composite). The study will only require the sampling of 1 vial of whole blood for the dosage of HCQ (that would be centralized and performed in PITIE-SALPETRIERE Hospital at the completion of the study). The patients and the physicians will also have adherence self-questionnaires to complete, and the physicians will complete a patient data sheet.
The end points are adherence of the treatment in the whole group, and subgroups, adherence according to the severity of SLE, and the relationship between patient's questionnaires, physician evaluation of adherence and blood HCQ dosage.
If investigators confirm their previous data, this study might demonstrate that a significant proportion of patient candidates for treatment escalation are in fact nonadherent to the treatment. It might further demonstrate the interest of HCQ concentrations monitoring, both in "real life" and in therapeutic study in SLE as it may avoid unnecessary, expensive or even hazardous regimen escalation.
|Study Type :||Observational|
|Actual Enrollment :||307 participants|
|Official Title:||International Prospective Study on Adherence to Treatment in Patients With Active Systemic Lupus Erythematosus|
|Study Start Date :||January 2013|
|Actual Primary Completion Date :||December 2015|
|Actual Study Completion Date :||March 2016|
- Adherence to the treatment in the whole group. [ Time Frame: participants will be followed for the duration of hospital stay, an expected average of 1 ]The end points are adherence of the treatment in the whole group(defined by very low blood HCQ concentration)
- Secondary outcome [ Time Frame: up to 3 weeks ]
Adherence according to central nervous system, to pregnancy, to the severity of SLE, to the center and the country.
Adherence in the group of patients fulfilling the eligibility criteria of studies on monoclonal antibodies, The relationship between patients questionnaires, physician evaluation of adherence and blood HCQ dosage Interest of MASRI and Morisky questionnaires in the prediction of non-adherence Factors associated with poor adherence
The socio-economic aspect of blood HCQ concentration measurement Pharmacokinetics studies on HCQ, with comparison to another cohort
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01509989
|Paris, France, 75679|
|Principal Investigator:||Nathalie Costedoat-Chalumeau, MD||Service de Médecine Interne, Hopital Cochin, 27, rue du Faubourg St Jacques, 75014 Paris, France. Email : firstname.lastname@example.org|
|Principal Investigator:||Michelle Petri, MD||Dept of Rheumatology, 1830 Building, Suite 7500. Email: email@example.com|
|Principal Investigator:||Jill Buyon, MD||560 First avenue, TCH-407, New York-NY 10016. Email: firstname.lastname@example.org|
|Principal Investigator:||Ann Clarke, MD||Lupus Clinic, Montreal General Hospital, Room A6163, 1650 Cedar Ave, Montreal, Quebec, Canada, H3G 1A4. Email: email@example.com|
|Principal Investigator:||Frederic Houssiau, MD||Rheumatology Unit, Internal Medicine Department, Cliniques universitaires Saint-Luc, Université catholique de Louvain,Bruxelles, Belgium. Email: Frederic.Houssiau@uclouvain.be|
|Principal Investigator:||Guillermo Ruiz-Irastorza, MD||Autoimmune Disease Research Unit, Internal Medicine Department,Hospital de Cruces, University of the Basque Country, Barakaldo, Spain. Email: firstname.lastname@example.org|
|Principal Investigator:||Ricard Cervera, MD||Department of Autoimmune Diseases, Hospital Clínic, email@example.com Barcelona, Catalonia, Spain. Email: firstname.lastname@example.org|
|Principal Investigator:||David Isenberg, MD||Department Inflammation, UCL Division of Medicine, Room 331 The Windeyer Building, 46 Cleveland Street, London, England. Email: email@example.com|
|Principal Investigator:||Yehuda Shoenfeld, MD||Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer 52621, Israel. Email: firstname.lastname@example.org|
|Principal Investigator:||Ronald F. van Vollenhoven, MD||Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska University Hospital, D10:0, Department of Rheumatology, 17176 Stockholm, Sweden. Email: Ronald.van.Vollenhoven@ki.se|
|Principal Investigator:||Eric Hachulla, MD||Service de Médecine Interne, Hôpital Claude Huriez, 1, place Verdun, 59000 Lille. Email: email@example.com|
|Principal Investigator:||Jean-François Viallard, MD||Service de Médecine Interne, Hôpital Haut Lévêque, Centre François Magendie, 1, avenue Magellan, 33604 Pessac Cedex. Email: firstname.lastname@example.org|
|Principal Investigator:||Loïc Guillevin, MD||Service de Médecine Interne, Hôpital Cochin, 27, rue du Faubourg Saint-Jacques, 75679 PARIS Cedex 14. Email: email@example.com|
|Principal Investigator:||Luc Mouthon, MD||Service de Médecine Interne, Hôpital Cochin, 27, rue du Faubourg Saint-Jacques, 75679 PARIS Cedex 14. Email: firstname.lastname@example.org|
|Principal Investigator:||Veronique Leguern, MD||Service de Médecine Interne, Hôpital Cochin, 27, rue du Faubourg Saint-Jacques, 75679 PARIS Cedex 14.|
|Principal Investigator:||Jean-Charles Piette, MD||Service de Médecine Interne, Hopital Pitié-Salpêtrière, 47-83 Boulevard de l'hôpital, 75013 Paris, France. Email: email@example.com|
|Principal Investigator:||Lionel Galicier, MD||Service Immuno Clinique|
|Principal Investigator:||Anne Laure Fauchais, MD||Service de Médecine interne, Hôpital Dupuytren, 2, avenue Martin Luther King 87042 Limoges cedex|
|Principal Investigator:||Holy Harifidy Bezanahrv, MD||Service de Médecine interne, Hôpital Dupuytren, 2, avenue Martin Luther King 87042 Limoges cedex|
|Principal Investigator:||Christophe deligny, MD||Service de Médecine interne (3C), CHU de Martinique, Hôpital Pierre-Zobda-Quitman, CS 90631-97261 Fort de France cedex|
|Principal Investigator:||Sandra Navarra, MD||University of Santo Tomas Hospital, España Boulevard, Sampaloc, Manila, Philippines|